Abstract:Alzheimer's disease (AD) is a devastating neurodegenerative disorder without cure. Among the suggested pathogenic factors of AD development, amyloid-beta (Aß) and tau have attracted extensive attention for drug discovery campaign. Recently, tau proteins, especially tau oligomers, have been shown critical roles in connection with synaptic impairment and cognition decline in AD. Consequently tau-directed drug discovery has been emerging as a new direction for development of effective AD-modifying agents, especially given the unsuccessful clinical trials of Aß targeted therapies. A rationally designed small molecule bivalent compound, ZCM-I-1, from the structures of curcumin and melatonin was characterized to inhibit the aggregation of tau441, remodel the aggregates of tau441, and rescue MC65 cells from tau-induced cytotoxicity by biochemical, biophysical and cellular assays. Our studies demonstrated that ZCM-I-1 efficiently remodeled the tau441 aggregates at a 1:2 ratio in a Thioflavin T fluorescence based assay. When compared to EGCG, a known tau aggregation inhibitor, ZCM-I-1 exhibited significantly improved efficacy. Transmission electron microscopy studies also confirmed the remodeling effects of ZCM-I-1 on tau441 fibrils. Notably, our studies on the aggregation of tau441 also identified ZCM-I-1 as an aggregation inhibitor with an IC50 of 20.05 ± 1.28 uM. In a cellular AD model, ZCM-I-1 efficiently protected MC65 cells from extracellular tau441 fibril induced cytotoxicity. Our studies established that ZCM-I-1 exhibits promising inhibitory activity on tau aggregation. ZCM-I-1 also shows activity to restructure tau441 aggregates to less toxic species. Combining the results of our previous studies of ZCM-I-1 on Aß and oxidative stress, the results strongly encourage further development of ZCM-I-1 and analogs as novel and effective disease modifying agents for AD.

Revealing the Amyloid Β-Protein with Zinc Finger Protein of Micronucleus During Alzheimer's Disease Progress by a Quaternary Ammonium Terpyridine Probe.

[In Vitro Early Detection of Amyloid Plaques in Alzheimer's Disease by Pittsburgh Compound B-modified Magnetic Nanoparticles].

A Novel Magnetic Nanoparticle for Early Detection of Amyloid Plaques in Alzheimer's Disease.

A Novel Viscosity Sensitive Hemicyanine Fluorescent Dye for Real-Time Imaging of Amyloid-Β Aggregation

Targeting Zincosomes to Unveil Lysosomal Zinc ion Dynamics and Their Role in Exacerbating Alzheimer's Pathology

In Vivo Target Bio-Imaging of Alzheimer's Disease by Fluorescent Zinc Oxide Nanoclusters.

Protein Aggregation Linked to Alzheimer's Disease Revealed by Saturation Transfer MRI

N-Methyl Mesoporphyrin IX As an Effective Probe for Monitoring Alzheimer’s Disease Β-Amyloid Aggregation in Living Cells

Preparation of Nanomolecular Probe and Its Effect on the Degradation of Amyloid Β-Protein in Alzheimer’s Disease

Protein aggregation linked to Alzheimer's disease revealed by saturation transfer MRI.

Light-controlled Fluorescent Probes for Precisely Monitoring Brain Amyloid-Β Aggregates in Alzheimer's Disease

Investigation of the Subcellular Neurotoxicity of Amyloid‐β Using a Device Integrating Microfluidic Perfusion and Chemotactic Guidance

IDENTIFICATION OF A SMALL MOLECULE INHIBITOR OF TAU AGGREGATION

Unlocking the Molecular Variations of a Micron-Scale Amyloid Plaque in an Early Stage Alzheimer’s Disease by a Cellular-Resolution Mass Spectrometry Imaging Platform

Metallosupramolecular complex targeting an α/β discordant stretch of amyloid β peptide

Rational design of a high-affinity fluorescent probe for visualizing monitoring the amyloid β clearance effect of anti-Alzheimer's disease drug candidates

Benzothiazolium Derivative-Capped Silica Nanocomposites for β-Amyloid Imaging In Vivo

Tailoring near-infrared amyloid-β probes with high-affinity and low background based on CN and amphipathic regulatory strategies and in vivo imaging of AD mice

High-fidelity imaging of amyloid-beta deposits with an ultrasensitive fluorescent probe facilitates the early diagnosis and treatment of Alzheimer's Disease

A hemicyanine derivative for near-infrared imaging of β-amyloid plaques in Alzheimer's disease.

In Vivo Rapid Fluorescence Imaging of Alzheimer’s Disease Through Accurate Target Bio-Marking of Zinc Gluconate